Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sitaxsentan: Phase IIb/III

Full data for the placebo-controlled, 12-week, double-blind U.S. Phase IIb/III STRIDE trial in 178 patients showed the 300 mg dose gave an increase

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE